Comparing the FDA new drug approval lists from 2023 and 2024 reveals a significant difference in the size of the companies that achieved the regulatory triumphs. In 2023, among the 68 FDA approvals ...
Cost advantages concentrated in higher OOP tiers: only 15% of all prescriptions were cheaper, but MCCPDC undercut insurance for ~82% of fills when OOP exceeded $15. Therapeutic areas with frequent ...
Lev’s reporting has explored Americans’ deadly hostility to addiction medications, subpar treatment offered in jails and prisons, shifts in the illicit drug supply and consumption behavior, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results